Dr Anny Fortin, MSc, PhD - Head of Research / Project Leader D121
Head of Research / Project Leader D121
Anny Fortin has a doctorate in Biochemistry from McGill University. She cumulates 13 years of experience in the corporate sector in the field of genetics, drug target identification, anti-infectious drug development and global health. She has been the project leader for D121 since 2008: general program design, supervision of the preclinical program and of the formulation and analytical platform development, coordination of the regulatory and IP strategies, the establishment and maintenance of relationships with external advisors, academic collaborators and CRO’s. She is trained in Good clinical practices and participated in the design of the early clinical program (Phase I and II) for D121. Anny Fortin is also an executive member of the Scientific Board of our company.
Hans Platteeuw, MSc – Head of Pharmaceutical R&D and Intellectual Property
Head of Pharmaceutical R&D and Intellectual Property
Hans Platteeuw holds a master’s degree in Chemistry from the University of Nijmegen (the Netherlands) and has almost 20 years of experience in pharmaceutical product development and innovation. He is very talented in translating lead compounds into pharmaceutical products that can be made cost effectively and put on a shelf in a pharmacy. He is the inventor on 30+ patents for various companies, i.e. Synthon, Dafra Pharma, Disphar, Pantharei Bioscience and Chamaeleo Pharma.
Dr. Ludo Haazen, MD - Head of Medical Affairs & Pharmacovigilance
Head of Medical Affairs & Pharmacovigilance
Ludo Haazen obtained his medical degree from the Catholic University of Leuven in Belgium in 1985. He then led several clinical development projects for pharmaceutical companies including Roche SA, Janssen Research Foundation (JNJ), Orthovita INc, TiGenix nv, and others, and this in numerous therapeutic areas. He has cumulated over 25 years of experience in clinical development and medical affairs, from first-in-man to post marketing studies. He has a deep understanding of the drug development business and was involved in two biotech start-up companies. He also teaches in pharmaceutical medicine at the Free University of Brussels.
Caroline Jansen, MA - Founder
Caroline Jansen is the founder of Oblita Therapeutics and takes up the responsibility for overall business management. She has a background of 15 years in public affairs (local authorities, federal/Belgian government and European parliament) and obtained a MA in Political Science at the Catholic University of Leuven. She then specialized in International Diplomacy and Management at Stellenbosch University (South-Africa) and obtained several management certificates afterwards (as well in private sector as public sector management).
She used to work for different parliaments (Belgian and European) as well as a cabinet advisor for the Prime Minister of Belgium and for the Belgian Minister of Economics, Foreign Trade, Energy and Science Policy.
She continued her career in advising on public affairs within pharmaceutical industry. Her background also includes working in the Lobby industry (the largest employer’s / entrepreneur’s organization in Belgium) as a Director of Services for Companies and as a Director Lobby & Public Affairs.